There was no significant difference between study groups in 60-day in-hospital mortality ( 28.5 % with rosuvastatin and 24.9 % with placebo , P = 0.21 ) or in mean ( SD ) ventilator-free days ( 15.110.8 with rosuvastatin and 15.111.0 with placebo , P = 0.96 ) .